UOC
NAMS icon

UBS O'Connor’s NewAmsterdam Pharma NAMS Stock Holding History

UBS O'Connor’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-45,000
Closed -$416K – 573
2023
Q3 		$416K Buy
+45,000
New +$487K 0.01% 415

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS O'Connor's NAMS Position: Q4 2023 in Review

UBS O'Connor sold out of NewAmsterdam Pharma (NAMS) in Q4 2023, closing a stake of 45,000 shares — an estimated $416K sold.

UBS O'Connor first reported a position in NAMS in Q3 2023 and held it in 1 quarter. The position peaked at $416K in Q3 2023. 32 funds tracked by Wall St. Rank hold NAMS as of Q4 2023.

  • UBS O'Connor reported no remaining NewAmsterdam Pharma position as of Q4 2023 after selling out during the quarter.
  • UBS O'Connor sold 45,000 NewAmsterdam Pharma shares in Q4 2023, an estimated $416K.
  • UBS O'Connor first reported a position in NewAmsterdam Pharma in Q3 2023 and held it in 1 quarter.
  • UBS O'Connor's NewAmsterdam Pharma position peaked at $416K in Q3 2023.
  • 32 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q4 2023.

Based on UBS O'Connor's 13F filing for Q4 2023, filed 14 Feb 2024.